Thursday, June 22, 2017

Cidara’s CD101 flunks mid-stage study in acute yeast infections; shares plummet 35% premarket – Seeking Alpha

February 21, 2017 by  
Filed under Latest Yeast Infection Help


Endpoints News

Cidara's CD101 flunks mid-stage study in acute yeast infections; shares plummet 35% premarket
Seeking Alpha
Thinly traded micro cap Cidara Therapeutics (NASDAQ:CDTX) drops 35% premarket on average volume in response to its announcement that its topical formulation of CD101 failed to demonstrate a sufficient treatment effect in a Phase 2 clinical trial in …
Cidara Antifungal Flunks in Phase 2 Clinical Trial, Sinking SharesXconomy

all 23 news articles »

Brought to you by Google News. Read the rest of the article here

Facebooktwittergoogle_plusredditpinterestlinkedinmail

Speak Your Mind

Tell us what you're thinking...
and oh, if you want a pic to show with your comment, go get a gravatar!

Before you post, please prove you are sentient.

What is 8 times 9?